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Patients	with	Kallmann	syndrome	(KS)	have	hypogonadotropic	hypogonadism	caused	by	a	deficiency	of	
gonadotropin-releasing	hormone	(GnRH)	and	a	defective	sense	of	smell	related	to	olfactory	bulb	aplasia.	
Based	on	the	findings	in	a	fetus	affected	by	the	X	chromosome–linked	form	of	the	disease,	it	has	been	sug-
gested	that	hypogonadism	in	KS	results	from	the	failed	embryonic	migration	of	neuroendocrine	GnRH1	
cells	from	the	nasal	epithelium	to	the	forebrain.	We	asked	whether	this	singular	observation	might	extend	
to	other	developmental	disorders	that	also	include	arrhinencephaly.	We	therefore	studied	the	location	of	
GnRH1	cells	in	fetuses	affected	by	different	arrhinencephalic	disorders,	specifically	X-linked	KS,	CHARGE	
syndrome,	trisomy	13,	and	trisomy	18,	using	immunohistochemistry.	Few	or	no	neuroendocrine	GnRH1	
cells	were	detected	in	the	preoptic	and	hypothalamic	regions	of	all	arrhinencephalic	fetuses,	whereas	large	
numbers	of	these	cells	were	present	in	control	fetuses.	In	all	arrhinencephalic	fetuses,	many	GnRH1	cells	
were	present	in	the	frontonasal	region,	the	first	part	of	their	migratory	path,	as	were	interrupted	olfactory	
nerve	fibers	that	formed	bilateral	neuromas.	Our	findings	define	a	pathological	sequence	whereby	a	lack	of	
migration	of	neuroendocrine	GnRH	cells	stems	from	the	primary	embryonic	failure	of	peripheral	olfactory	
structures.	This	can	occur	either	alone,	as	in	isolated	KS,	or	as	part	of	a	pleiotropic	disease,	such	as	CHARGE	
syndrome,	trisomy	13,	and	trisomy	18.
Introduction
Gonadotropin-releasing hormone (GnRH) controls the pituitary-
gonadal axis (1). Embryological studies in various vertebrate species 
have shown that neuroendocrine GnRH cells (i.e., GnRH1-synthe-
sizing neurons) migrate from the medial part of the nasal epithe-
lium up to the forebrain. In mammals, they migrate in close asso-
ciation with fibers of the vomeronasal and terminal nerves (2, 3). 
Upon reaching the base of the telencephalon, they penetrate the 
brain together with the central processes of the terminal nerves, just 
caudal to the olfactory bulb anlage, and make their way along the 
medial wall of the cerebral hemisphere to the preoptic/hypothalam-
ic region, where they ultimately settle. Migration of these cells begins 
during the sixth embryonic week in humans (3). This is also when 
fibers of the olfactory and terminal nerves first come into contact 
with the brain, shortly before the emergence of the olfactory bulbs.
Kallmann syndrome (KS) is a developmental disorder that com-
bines hypogonadotropic hypogonadism with anosmia/hyposmia, 
related to the aplasia/hypoplasia of the olfactory bulbs and tracts (4). 
It has been proposed that disrupted migration of neuroendocrine 
GnRH cells is responsible for the hypogonadism, based on the exam-
ination of a single 19-week-old male fetus carrying a chromosomal 
deletion at Xp22.3 that included KAL1 (5–7), the gene responsible 
for the X chromosome–linked form of the syndrome, KAL1. This 
fetus had no olfactory bulbs, and there was a complete absence of 
GnRH1 cells in the brain, whereas clusters of these cells were found 
in the nasal region and on the dorsal surface of the ethmoid bone 
cribriform plate, together with entangled fibers of the olfactory and 
terminal nerves that did not contact the forebrain (8).
Arrhinencephaly (i.e., absence of the olfactory bulbs) is observed 
in KS and some pleiotropic developmental diseases, including 
CHARGE syndrome (9), trisomy 13 (also known as Patau syn-
drome; ref. 10), and trisomy 18 (also known as Edwards syndrome; 
ref. 11). CHARGE refers to coloboma of the eye, heart defect, cho-
anal atresia, retarded growth and development, genital hypoplasia, 
external ear anomalies and deafness (12); however, many individu-
als with CHARGE syndrome do not have all these clinical features, 
and other developmental anomalies can also be present (13). In 
particular, hypoplasia/aplasia of the inner ear semicircular canals 
has consistently been found in patients (9). Moreover, a recent study 
concluded that most, if not all, CHARGE patients have both olfac-
tory bulb hypoplasia/aplasia and hypogonadotropic hypogonadism 
(14); that is, the KS-defining features. In approximately two-thirds 
of cases, CHARGE syndrome is caused by neomutations in CHD7 
(15). Mutations in this gene have been identified in a few patients 
initially diagnosed with KS (16, 17), thus reinforcing the idea of a 
tight pathological relationship between the diseases. Therefore, we 
asked whether the hypogonadism in CHARGE syndrome could 
result from defective migration of neuroendocrine GnRH cells, 
as in the KAL1 fetus. We further asked whether defective migra-
tion of these cells is also associated with the absence of the olfac-
tory bulbs found in some individuals with trisomy 13 or trisomy 
18. Even though hypogonadotropic hypogonadism has not to our 
knowledge been reported in these genetic conditions (presumably 
because of short life expectancy), cryptorchidism and micropenis are 
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common in affected males (10). We thus studied the location of 
GnRH1-immunoreactive cells in 4 different arrhinencephalic fetuses: 
another KAL1 male fetus, aged 25 weeks, carrying a nonsense muta-
tion in KAL1; a male fetus, aged 23 weeks, with CHARGE syndrome 
due to a frame-shifting mutation in CHD7; a female fetus, aged 18 
weeks, with trisomy 13 (47, XX+13 karyotype); and a male fetus, 
aged 35 weeks, with trisomy 18 (47, XY+18 karyotype) (see Supple-
mental Results and Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI43699DS1).
Results and Discussion
Arrhinencephalic fetuses have few or no neuroendocrine GnRH cells in the 
preoptic and hypothalamic areas. In 2 control fetuses aged 22 and 24 
weeks, numerous GnRH1-immunoreactive cells were detected in 
the forebrain. They were found singly, in pairs, or, rarely, in small 
clusters. Most of these cells were neuroendocrine cells that were 
found in the medial preoptic area, the retrochiasmatic area, and 
the anterior and medial basal hypothalamus (Figure 1, Table 1, 
and ref. 8). In contrast, we detected few or no GnRH1 cells in the 
preoptic and hypothalamic areas of the 4 arrhinencephalic fetus-
es. In addition, in the control, trisomy 13, and trisomy 18 fetuses, 
scattered GnRH1 cells were found close to the lateral ventricles, 
at various emplacements from the dorsal thalamus to the fornix 
(Figure 1, Table 1, and ref. 18). These cells presumably represent 
misrouted GnRH1 neurons.
Arrhinencephalic fetuses, but not control 
fetuses, have many GnRH1 cells in the fronto-
nasal region. In all the arrhinencephalic 
fetuses, numerous GnRH1 cells were 
found in the upper nasal region and/or 
on the dorsal aspect of the ethmoid bone 
cribriform plate. These cells occasionally 
formed small clusters in ganglia of the ter-
minal nerve (Figure 2, E–H). In contrast, 
we did not detect GnRH1 cells in the fron-
tonasal region in any of the age-matched 
control fetuses. Notably, present on the 
dorsal aspect of the cribriform plate in 
the KAL1 and CHARGE fetuses were 
bilateral spherical structures consistent 
with neuromas, for they were composed of 
entangled nerve fibers, as shown by βIII-
tubulin immunostaining. Such protrusive 
structures were not clearly identified in the 
2 trisomic fetuses, but we did observe simi-
lar bulges on both sides of the crista galli 
in another arrhinencephalic trisomy 13 
fetus, aged 23 weeks, whose brain could not 
be analyzed for GnRH1 immunoreactivity 
(Figure 2, A–D). The number of GnRH1-
immunoreactive cells detected on brain sec-
tions and sections of the frontonasal region 
in the 4 arrhinencephalic fetuses and 2 con-
trol fetuses are presented in Table 1.
The olfactogenital fetopathological sequence. 
This study of human fetuses lacking olfac-
tory bulbs showed in all cases an accumula-
tion of GnRH1 cells in the first, extracere-
bral part of their migratory path. Although 
these cells had left the nasal epithelium, they 
seemed to be arrested in the frontonasal region, together with inter-
rupted nerve fibers. Accordingly, few or no neuroendocrine GnRH 
cells were detected in the preoptic/hypothalamic regions of these 
fetuses (Figure 3). Our findings, combined with the previous study 
of a KAL1 fetus (8), thus delimit a pathological entity that can be 
defined clinically by the association of hypogonadotropic hypogo-
nadism with anosmia (KS) and anatomically by the concomitance of 
olfactory bulb aplasia and accumulation of neuroendocrine GnRH 
cells outside the brain, together with the premature termination of 
olfactory and terminal nerve fibers. The failure of GnRH1 cell migra-
tion is likely to be the consequence of interrupted terminal nerve 
fibers, which normally serve as guidance cues for the penetration of 
these cells into the forebrain (2, 3). Our conclusions are primarily 
based on the study of 2 fetuses affected by the KAL1 genetic form 
(ref. 8 and the present study). To our knowledge, histopathological 
observations of human individuals affected by other genetic forms 
of KS, caused by loss-of-function mutations in FGFR1 (19), FGF8 
(20), PROKR2, or PROK2 (21), are not yet available. These forms 
indeed do not involve life-threatening developmental anomalies 
that may lead to medical interruption of pregnancy and fetopatho-
logical examination. However, several mouse models of KS have 
been analyzed, which are useful to extend the pathological obser-
vations made in the KAL1 human fetuses to other genetic forms. 
Both Prokr2 and Prok2 knockout mice have a marked decrease in the 
Table 1
Number of GnRH1 cells detected on sections of forebrain and frontonasal region
Fetus	 Forebrain	 Frontonasal	region
	 Preoptic/	 	Periventricular	 Upper	nasal	 Dorsal	aspect	of	
	 hypothalamic	area	 (lateral	ventricles)	 region	 cribriform	plate
Control (22 weeks) 150 43 0 0
Control (24 weeks) 169 56 0 0
KAL1 0 0 39 202
CHARGE syndrome 5A 0 179 300
Trisomy 13 10A 72 272 243
Trisomy 18 0 46 0 132
ALess than 2% of the immunoreactive cells counted in the frontonasal region.
Figure 1
Distribution of GnRH1-immunoreactive cells in a normal fetal brain. Left: Mayer hemalun stain-
ing of a sagittal section of the forebrain from a 24-week-old control fetus (rostral region at left). 
Arabic numerals denote the locations of GnRH1-immunoreactive cells: 1–5 are typical of neuro-
endocrine GnRH1 cells, whereas 6–9 presumably correspond to some misrouted GnRH1 neu-
rons. Right: detailed microscopic views of regions 4 and 9, showing GnRH1 neurons (arrows). 
LV, lateral ventricle. Scale bars: 3 mm (left); 50 μm (right).
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number of GnRH1 cells present in the preoptic area of the brain (22, 
23), which, in the Prok2-null mice, could be attributed to a defect 
in the embryonic migration of these cells. Indeed, in E13.5 mutant 
mice, GnRH1 cells, after crossing the cribriform plate, seemed to be 
trapped in a spherical-shaped abnormal structure (23), reminiscent 
of the neuromas we observed in the human fetuses. A similar struc-
ture was also reported in Prokr2-null mice as early as E12.5 (22), 
by the time axonal fibers of the olfactory and terminal nerves first 
come into contact with the rostral forebrain in a normal mouse. 
This is indicative of a primary failure of these axons to penetrate 
the brain. Mice deficient in Fgfr1 or Fgf8 because of hypomorphic 
mutations also have a markedly decreased number or a complete 
absence, respectively, of GnRH1 cells in the preoptic area (20, 24). 
In the Fgf8 hypomorphs, however, GnRH1 cells never emerge from 
the nasal epithelium (24), which suggests the existence of an earlier 
defect expected to mask the GnRH1 cell migration defect.
KS in pleiotropic developmental diseases. From this and other stud-
ies, it appears that the olfactogenital pathological sequence defined 
herein can be either isolated or associated with various develop-
mental anomalies. Some of these, including renal agenesis, cleft lip 
or palate, hypodontia, and bimanual synkinesia, were unambigu-
ously ascribed to specific gene defects responsible for KS several 
years ago (4). While more recent clinical and genetic studies already 
supported the notion that CHARGE syndrome includes KS (14, 16, 
17), our findings in the CHARGE fetus not only confirm this view, 
but also indicate that in the 2 pathological conditions, hypogonad-
ism presumably results from the same fetopathological sequence. 
To our knowledge, a connection between the reported anomalies of 
the olfactory and reproductive systems in trisomy 13 and trisomy 
18 had not previously been suspected. The study of the trisomic 
human fetuses was most informative, especially in the absence of 
animal models for these chromosomal anomalies. In addition, 
assuming that only 1 gene on each of the chromosomes 13 and 18 
is responsible for the olfactogenital sequence in these fetuses, some 
patients with KS might carry gain-of-function mutations in these 
putative genes. Indeed, mutations in the genes already identified 
only account for approximately 30% of all KS cases (4).
In conclusion, we have extended the failure of neuroendocrine 
GnRH cell migration, initially reported in an individual with KAL1, 
to 3 different developmental diseases that share olfactory bulb apla-
sia: CHARGE syndrome, trisomy 13, and trisomy 18. Based on the 
connection between the peripheral olfactory system and the path of 
GnRH1 cells in embryonic life, as well as the olfactogenital pathologi-
cal sequence defined herein, we surmise that such a GnRH1 cell migra-
tion defect occurs in most, if not all, arrhinencephalic conditions.
Methods
This study was approved by the national research ethics committee (Agence 
de Biomédecine, Paris, France).
Human tissues. Fetuses were obtained from medically terminated pregnan-
cies, with parents’ written informed consent. Termination of pregnancy was 
carried out by intracardiac injection of 25 U pentothal, followed by labor 
Figure 2
Neuromas and accumulation of GnRH1-immunoreactive cells in the frontonasal region of arrhinencephalic fetuses. (A–C) Coronal sections of 
the frontonasal region in the KAL1 fetus and 23-week-old trisomy 13 and control fetuses, immunostained with an anti–βIII-tubulin antibody. The 
brains have been removed. In the KAL1 and trisomy 13 fetuses, bilateral spherical structures corresponding to neuromas (arrowheads) are 
visible on the dorsal aspect of the cribriform plate (cp) stained with Alcian blue. oe, olfactory epithelium. (D) Endocranial view of the cribriform 
plate region of the ethmoid bone in the CHARGE fetus. Abnormal spherical structures (arrowheads) were present on both sides of the crista 
galli. Inset: section from one of the spherical structures. The entangled nerve fibers that make up the neuroma were stained using an anti–βIII-
tubulin antibody. (E–H) Coronal sections corresponding to the boxed regions in B from KAL1, CHARGE, trisomy 13, and trisomy 18 fetuses. 
Sections were immunostained using an anti-GnRH1 antibody. In all fetuses, GnRH1 cells were seen in the upper nasal region (region 1) and/or 
on the dorsal aspect of the cribriform plate (region 2). Note the presence of GnRH1 cells only on the dorsal aspect of the cribriform plate for the 
35-week-old trisomy 18 fetus. Scale bars: 1 mm (A–D); 200 μm (D, inset); 30 μm (E–H).
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induction. Gestational ages of the fetuses were established by crown-rump 
length measurement during first-trimester ultrasonography examination, 
confirmed at autopsy by fetal biometry and evaluation of skeletal and organ 
maturation. The forebrains from 4 arrhinencephalic fetuses aged 18, 23, 
25, and 35 weeks and 2 control fetuses aged 22 and 24 weeks were analyzed. 
Brains were removed and fixed in a 4% formaldehyde solution containing 
154 mM NaCl and 16 mM ZnSO4 for 3–4 weeks. For frontonasal region 
analysis, all arrhinencephalic fetuses were compared with age-matched con-
trol fetuses. A fragment of about 1 cm3 of the frontonasal region was taken 
from each fetus, fixed in the formaldehyde solution for 1 week, and decalci-
fied in 0.5 M EDTA for another week. The forebrains and frontonasal region 
fragments were embedded in paraffin and cut in sagittal and coronal slices, 
respectively. Serial sections (4 μm thick) were then taken on Superfrost Plus 
slides (Thermo Scientific) using a Microm HM340E microtome. 1 of 10 sec-
tions was stained with H&E for histological analysis.
Immunohistochemistry. Immunochemistry analysis was conducted as pre-
viously described (8). Primary antibodies were rabbit anti-GnRH1 (1:2,000 
dilution; catalog no. ab5617; Abcam) directed against the human GnRH1 
decapeptide (cross-reaction with GnRH2, <0.1% by RIA using 125I GnRH1 
as radio ligand; ref. 18) and mouse anti-human βIII-tubulin (1:50 dilution; 
Chemicon) for detection of GnRH1 cells and nerve fibers, respectively. 
Immunostainings used the UltraTech HRP kit (Immunotech). Sections 
were counterstained with Mayer hemalun. A few sections from the fronto-
nasal region were counterstained with Alcian blue to reveal skeletal struc-
tures. Images were acquired using a DMR microscope (Leica) with a DFX-
900 camera (Sony) and Matrox Inspector software (version 4.1; Matrox). 
We analyzed 144–173 consecutive brain sections and 45–100 consecutive 
frontonasal sections for each fetus. For quantification of GnRH1 cells, 
all sections were analyzed separately by 2 independent investigators, with 
common reevaluation when necessary. Special care was taken not to dou-
ble-count GnRH cells on adjacent sections.
Acknowledgments
We thank Marie-Noelle Lotiquet, Béatrice Bartolt, Véronique 
Kyroudis, Rémi Pineau, Mélanie Dumand, Chrystel Leroy, and 
Corinne Fouveaut for technical help and Henryk Urbanski, Alon 
Chen, and Christine Petit for fruitful discussions. The work was sup-
ported by the Agence Nationale de la Recherche (ANR-09-GENO-
017-01) and NIH grant HD-29186. L. Teixeira was supported by a 
fellowship from the Fondation pour la Recherche Médicale.
Received for publication May 14, 2010, and accepted in revised 
form July 28, 2010.
Address correspondence to: Jean-Pierre Hardelin, Département de 
Neuroscience, Institut Pasteur, 25 rue du Docteur Roux, F-75724 
Paris cedex, France. Phone: 33.1.45.68.88.91; Fax: 33.1.40.61.34.42; 
E-mail: jean-pierre.hardelin@pasteur.fr.
Figure 3
Distribution of GnRH1-immunoreactive cells in the forebrains and frontonasal regions of the 4 arrhinencephalic fetuses and a control fetus. Red 
dots denote GnRH1 cells. Green lines indicate the path of the olfactory and terminal nerve fibers. The intracerebral fluid compartment is shaded 
gray. In the control fetus, GnRH1 cells were present in the preoptic and hypothalamic areas and were not detected in the frontonasal region. 
In addition, scattered, presumably misrouted GnRH1 neurons were found at several periventricular locations in the forebrain. In the arrhinen-
cephalic fetuses, GnRH1 cells accumulated along the broken path of the olfactory and terminal nerve fibers that do not make contact with the 
forebrain. Few or no neuroendocrine cells were found in the preoptic/hypothalamic region. Scattered, periventricular GnRH1 neurons were also 
detected in the trisomy 13 and trisomy 18 fetuses. Scale bars: 1 cm. ob, olfactory bulb; h, hypothalamus; t, thalamus.
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